Which has higher earnings & valuation, IVVD or SVRA?

Invivyd has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invivyd $53.43M 4.02 -$52.49M -$0.33 N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is IVVD or SVRA more profitable?

Savara has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -183.90% -59.73% -48.97% Savara N/A -90.28% -68.95%

Does the media prefer IVVD or SVRA?

In the previous week, Savara had 5 more articles in the media than Invivyd. MarketBeat recorded 8 mentions for Savara and 3 mentions for Invivyd. Invivyd's average media sentiment score of 0.93 beat Savara's score of 0.43 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MLTX or IVVD?

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Invivyd. MarketBeat recorded 4 mentions for MoonLake Immunotherapeutics and 3 mentions for Invivyd. Invivyd's average media sentiment score of 0.93 beat MoonLake Immunotherapeutics' score of 0.23 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ANL or IVVD?

Adlai Nortye has higher earnings, but lower revenue than Invivyd. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 180.96 -$35.53M N/A N/A Invivyd $53.43M 4.02 -$52.49M -$0.33 N/A

Is ANL or IVVD more profitable?

Adlai Nortye has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Adlai Nortye's return on equity of 0.00% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Invivyd -183.90% -59.73% -48.97%

Does the media favor ANL or IVVD?

In the previous week, Adlai Nortye had 9 more articles in the media than Invivyd. MarketBeat recorded 12 mentions for Adlai Nortye and 3 mentions for Invivyd. Invivyd's average media sentiment score of 0.93 beat Adlai Nortye's score of 0.29 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IVVD or KURA more profitable?

Invivyd has a net margin of -183.90% compared to Kura Oncology's net margin of -384.30%. Invivyd's return on equity of -59.73% beat Kura Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -183.90% -59.73% -48.97% Kura Oncology -384.30% -207.18% -45.17%

Does the media prefer IVVD or KURA?

In the previous week, Kura Oncology had 11 more articles in the media than Invivyd. MarketBeat recorded 14 mentions for Kura Oncology and 3 mentions for Invivyd. Invivyd's average media sentiment score of 0.93 beat Kura Oncology's score of 0.12 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 1 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is IVVD or JBIO more profitable?

Jade Biosciences has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Jade Biosciences' return on equity of -49.11% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -183.90% -59.73% -48.97% Jade Biosciences N/A -49.11% -45.62%

Does the media prefer IVVD or JBIO?

In the previous week, Jade Biosciences had 3 more articles in the media than Invivyd. MarketBeat recorded 6 mentions for Jade Biosciences and 3 mentions for Invivyd. Invivyd's average media sentiment score of 0.93 beat Jade Biosciences' score of 0.17 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jade Biosciences 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Invivyd (IVVD) Competitors

$0.70 -0.03 (-3.87%)

Closing price 04:00 PM Eastern

Extended Trading

$0.71 +0.01 (+1.66%)

As of 05:47 PM Eastern

Compare

IVVD vs. SVRA, MLTX, ANL, KURA, and JBIO

Should you buy Invivyd stock or one of its competitors? Invivyd's main competitors and comparable companies include Savara (SVRA), MoonLake Immunotherapeutics (MLTX), Adlai Nortye (ANL), Kura Oncology (KURA), and Jade Biosciences (JBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Invivyd compare to Savara?

Invivyd (NASDAQ:IVVD) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Savara has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Savara	N/A	-90.28%	-68.95%

Invivyd has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	4.02	-$52.49M	-$0.33	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

70.4% of Invivyd shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Invivyd currently has a consensus target price of $10.00, suggesting a potential upside of 1,272.50%. Savara has a consensus target price of $10.25, suggesting a potential upside of 110.04%. Given Invivyd's higher possible upside, equities analysts plainly believe Invivyd is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Savara	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Invivyd has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Savara has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

In the previous week, Savara had 5 more articles in the media than Invivyd. MarketBeat recorded 8 mentions for Savara and 3 mentions for Invivyd. Invivyd's average media sentiment score of 0.93 beat Savara's score of 0.43 indicating that Invivyd is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Invivyd beats Savara on 10 of the 16 factors compared between the two stocks.

How does Invivyd compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Invivyd has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Invivyd	$53.43M	4.02	-$52.49M	-$0.33	N/A

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Invivyd. MarketBeat recorded 4 mentions for MoonLake Immunotherapeutics and 3 mentions for Invivyd. Invivyd's average media sentiment score of 0.93 beat MoonLake Immunotherapeutics' score of 0.23 indicating that Invivyd is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 12.3% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MoonLake Immunotherapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Invivyd has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Invivyd	-183.90%	-59.73%	-48.97%

MoonLake Immunotherapeutics currently has a consensus target price of $28.50, suggesting a potential upside of 164.62%. Invivyd has a consensus target price of $10.00, suggesting a potential upside of 1,272.50%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.43
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Invivyd beats MoonLake Immunotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Invivyd compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Adlai Nortye currently has a consensus price target of $29.50, indicating a potential upside of 109.96%. Invivyd has a consensus price target of $10.00, indicating a potential upside of 1,272.50%. Given Invivyd's higher possible upside, analysts clearly believe Invivyd is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Adlai Nortye has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Adlai Nortye's return on equity of 0.00% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Invivyd	-183.90%	-59.73%	-48.97%

Adlai Nortye has higher earnings, but lower revenue than Invivyd.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	180.96	-$35.53M	N/A	N/A
Invivyd	$53.43M	4.02	-$52.49M	-$0.33	N/A

Adlai Nortye has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Invivyd has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 12.3% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Adlai Nortye had 9 more articles in the media than Invivyd. MarketBeat recorded 12 mentions for Adlai Nortye and 3 mentions for Invivyd. Invivyd's average media sentiment score of 0.93 beat Adlai Nortye's score of 0.29 indicating that Invivyd is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Adlai Nortye beats Invivyd on 10 of the 15 factors compared between the two stocks.

How does Invivyd compare to Kura Oncology?

Invivyd (NASDAQ:IVVD) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Invivyd has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Invivyd has a net margin of -183.90% compared to Kura Oncology's net margin of -384.30%. Invivyd's return on equity of -59.73% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Kura Oncology	-384.30%	-207.18%	-45.17%

Invivyd has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	4.02	-$52.49M	-$0.33	N/A
Kura Oncology	$67.48M	14.07	-$278.67M	-$3.37	N/A

70.4% of Invivyd shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Invivyd presently has a consensus target price of $10.00, indicating a potential upside of 1,272.50%. Kura Oncology has a consensus target price of $25.69, indicating a potential upside of 140.75%. Given Invivyd's higher probable upside, research analysts clearly believe Invivyd is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Kura Oncology had 11 more articles in the media than Invivyd. MarketBeat recorded 14 mentions for Kura Oncology and 3 mentions for Invivyd. Invivyd's average media sentiment score of 0.93 beat Kura Oncology's score of 0.12 indicating that Invivyd is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	1 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Invivyd beats Kura Oncology on 10 of the 16 factors compared between the two stocks.

How does Invivyd compare to Jade Biosciences?

Invivyd (NASDAQ:IVVD) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Invivyd has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	4.02	-$52.49M	-$0.33	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

Invivyd has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market.

70.4% of Invivyd shares are held by institutional investors. 12.3% of Invivyd shares are held by insiders. Comparatively, 23.1% of Jade Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Jade Biosciences had 3 more articles in the media than Invivyd. MarketBeat recorded 6 mentions for Jade Biosciences and 3 mentions for Invivyd. Invivyd's average media sentiment score of 0.93 beat Jade Biosciences' score of 0.17 indicating that Invivyd is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jade Biosciences has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Jade Biosciences' return on equity of -49.11% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Jade Biosciences	N/A	-49.11%	-45.62%

Invivyd currently has a consensus price target of $10.00, indicating a potential upside of 1,272.50%. Jade Biosciences has a consensus price target of $51.75, indicating a potential upside of 275.82%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

Jade Biosciences beats Invivyd on 9 of the 16 factors compared between the two stocks.

Get Invivyd News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVVD vs. The Competition

Export

Metric	Invivyd	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$206.45M	$3.83B	$7.14B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	-2.12	14.03	275.17	25.94
Price / Sales	3.86	1,174.74	566.39	83.63
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	0.67	16.11	10.80	6.27
Net Income	-$52.49M	-$22.69M	$3.50B	$382.13M
7 Day Performance	-14.22%	-3.47%	-2.01%	-1.35%
1 Month Performance	-15.19%	-12.67%	-7.53%	-5.60%
1 Year Performance	-57.29%	9.63%	3.34%	-1.53%

Invivyd Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVVD Invivyd	3.4043 of 5 stars	$0.70 -3.9%	$10.00 +1,327.8%	-55.3%	$206.45M	$53.43M	N/A	122	High Trading Volume
SVRA Savara	2.2297 of 5 stars	$4.71 -1.5%	$10.00 +112.3%	+42.3%	$972.85M	N/A	N/A	70	News Coverage Analyst Forecast
MLTX MoonLake Immunotherapeutics	2.0681 of 5 stars	$11.31 -0.6%	$28.50 +152.0%	+16.1%	$969.57M	N/A	N/A	130	Analyst Forecast
ANL Adlai Nortye	1.9664 of 5 stars	$15.05 +0.1%	$29.50 +96.0%	+712.1%	$968.48M	$18.06M	N/A	109	Analyst Upgrade High Trading Volume
KURA Kura Oncology	3.3259 of 5 stars	$10.53 -0.8%	$25.69 +143.9%	+13.1%	$940.76M	$77.23M	N/A	260	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVVD) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invivyd (IVVD) Competitors

IVVD vs. SVRA, MLTX, ANL, KURA, and JBIO

How does Invivyd compare to Savara?

Summary

How does Invivyd compare to MoonLake Immunotherapeutics?

Summary

How does Invivyd compare to Adlai Nortye?

Summary

How does Invivyd compare to Kura Oncology?

Summary

How does Invivyd compare to Jade Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invivyd (IVVD) Competitors

IVVD vs. SVRA, MLTX, ANL, KURA, and JBIO

How does Invivyd compare to Savara?

Is IVVD or SVRA more profitable?

Which has higher earnings & valuation, IVVD or SVRA?

Do institutionals & insiders hold more shares of IVVD or SVRA?

Do analysts rate IVVD or SVRA?

Which has more risk & volatility, IVVD or SVRA?

Does the media prefer IVVD or SVRA?

Summary

How does Invivyd compare to MoonLake Immunotherapeutics?

Which has better earnings & valuation, MLTX or IVVD?

Does the media refer more to MLTX or IVVD?

Do institutionals and insiders have more ownership in MLTX or IVVD?

Which has more risk and volatility, MLTX or IVVD?

Is MLTX or IVVD more profitable?

Do analysts rate MLTX or IVVD?

Summary

How does Invivyd compare to Adlai Nortye?

Do analysts rate ANL or IVVD?

Is ANL or IVVD more profitable?

Which has better valuation & earnings, ANL or IVVD?

Which has more volatility and risk, ANL or IVVD?

Do institutionals & insiders have more ownership in ANL or IVVD?

Does the media favor ANL or IVVD?

Summary

How does Invivyd compare to Kura Oncology?

Which has more volatility and risk, IVVD or KURA?

Is IVVD or KURA more profitable?

Which has better earnings & valuation, IVVD or KURA?

Do insiders & institutionals believe in IVVD or KURA?

Do analysts prefer IVVD or KURA?

Does the media prefer IVVD or KURA?

Summary

How does Invivyd compare to Jade Biosciences?

Which has higher valuation & earnings, IVVD or JBIO?

Which has more risk & volatility, IVVD or JBIO?

Do insiders and institutionals believe in IVVD or JBIO?

Does the media prefer IVVD or JBIO?

Is IVVD or JBIO more profitable?

Do analysts prefer IVVD or JBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools